Michael J. Campbell, Ph.D.
- Professor of Surgery
- Division of Surgical Oncology
Contact Information
Education
-
1978-82, University of Puget Sound, B.S., Biology
-
1978-82, University of Puget Sound, B.S., Mathematics
-
1983-87, Stanford University, Ph.D., Cancer Biology
Biography
Michael Campbell, Ph.D. received his doctoral degree in Cancer Biology from Stanford University where he remained as a postdoctoral fellow in Oncology. Dr. Campbell was appointed Assistant Professor of Surgery at Stanford University in 1992. He joined the UCSF faculty as Assistant Professor of Surgery in 1997.
Dr. Campbell's areas of interest in research include breast neoplasms, cancer vaccines, immunotherapy, immunologic adjuvants, immunologic and biological factors, gene therapy, immunology, and breast cancer.
Mentoring Overview
Dr. Campbell's research is focused on characterizing the immune landscape within tumors and its relationship to indolent or idle breast cancer (and DCIS), as well as investigating changes in immune infiltrates in the context of therapy. His lab has developed multiplex immunofluorescence staining panels and multispectral imaging protocols for various immune cell populations. Dr. Campbell has mentored 15 pre-doctoral students and 8 clinical fellows over the past 17 years at UCSF, all of whom have gone on to careers in medicine or science.
Trainee opportunities in Dr. Campbell's lab include participation in studies characterizing the tumor immune microenvironment in cancer and pre-cancerous lesions and identifying immune-related biomarkers of response to therapy, as well as pre-clinical studies evaluating new immunotherapeutic strategies. He has access to the over 1500 patients with serial samples from the I SPY-2 study, with the opportunity to predict response to novel and immune targeted treatments
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 52
- Chung R, Garratt J, Remer EM, Navin P, Blake MA, Taffel MT, Hackett CE, Sharbidre KG, Tu W, Low G, Bara M, Carney BW, Corwin MT, Campbell MJ, Lee JT, Lee CY, Dueber JC, Shehata MA, Caoili EM, Schieda N, Elsayes KM. Adrenal Neoplasms: Lessons from Adrenal Multidisciplinary Tumor Boards. Radiographics. 2023 Jul; 43(7):e220191. View in PubMed
- Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort. Cancer Res Commun. 2022 12; 2(12):1579-1589. View in PubMed
- Collins RA, DiGennaro C, Beninato T, Gartland RM, Chaves N, Broekhuis JM, Reddy L, Lee J, Deimiller A, Alterio MM, Campbell MJ, Lee YJ, Khilnani TK, Stewart LA, O'Brien MA, Alvarado MVY, Zheng F, McAneny D, Liou R, McManus C, Dream SY, Wang TS, Yen TW, Alhefdhi A, Finnerty BM, Fahey TJ, Graves CE, Laird AM, Nehs MA, Drake FT, Lee JA, McHenry CR, James BC, Pasieka JL, Kuo JH, Lubitz CC. Limited disease progression in endocrine surgery patients with treatment delays due to COVID-19. Surgery. 2022 Aug 29. View in PubMed
- Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ. Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection. NPJ Breast Cancer. 2021 May 25; 7(1):59. View in PubMed
- Mori H, Bolen J, Schuetter L, Massion P, Hoyt CC, VandenBerg S, Esserman L, Borowsky AD, Campbell MJ. Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence. J Mammary Gland Biol Neoplasia. 2020 12; 25(4):417-432. View in PubMed
- View All Publications